Cargando…
Ran GTPase-Activating Protein 1 Is a Therapeutic Target in Diffuse Large B-Cell Lymphoma
Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50% of patients experience long-term survival after current treatment; therefore, developing novel ther...
Autores principales: | Chang, Kung-Chao, Chang, Wei-Chao, Chang, Yao, Hung, Liang-Yi, Lai, Chien-Hsien, Yeh, Yu-Min, Chou, Yu-Wei, Chen, Chung-Hsuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819250/ https://www.ncbi.nlm.nih.gov/pubmed/24223200 http://dx.doi.org/10.1371/journal.pone.0079863 |
Ejemplares similares
-
Inter-Cellular Transport of Ran GTPase
por: Khuperkar, Deepak, et al.
Publicado: (2015) -
Bilateral lacrimal glands and paranasal sinus diffuse large B-cell lymphoma following lung mucosa-associated lymphoid tissue lymphoma in one patient
por: Huang, Chun-Hao, et al.
Publicado: (2021) -
The Fission Yeast Ran Gtpase Is Required for Microtubule Integrity
por: Fleig, Ursula, et al.
Publicado: (2000) -
Dynamic localisation of Ran GTPase during the cell cycle
por: Hutchins, James RA, et al.
Publicado: (2009) -
Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
por: Chang, Kung-Chao, et al.
Publicado: (2020)